Reply.

We appreciate the opportunity to respond to the letter by Conway and Molloy regarding our recent manuscript entitled "Ustekinumab for the treatment of giant cell arteritis" [1]. Our results demonstrated that ustekinumab (UST) administered every 8 weeks was well tolerated but did not prevent disease relapse in a significant proportion of giant cell arteritis (GCA) patients when used in combination with 6 months of prednisone. We acknowledge that a small sample size and the lack of a control group are important limitations of our study and agree with Conway and Molloy that further research is needed to assess the utility of UST more definitively in GCA.